US-based Thermo Fisher Scientific has partnered with Samsung Electronics to design, develop and market new point-of-care (POC) diagnostic solutions.

The new solutions will be used in key applications such as the detection of sepsis, drugs of abuse and therapeutic drug monitoring, as well as to detect cardiac problems and women’s health conditions.

Thermo Fisher Scientific clinical diagnostics business president Marc Tremblay said: "Samsung has developed a compelling and innovative suite of POC platforms.

"We look forward to working with Samsung to add some of our leading biomarkers and assays to their platforms to create a truly differentiated testing menu."

POC testing enables patient diagnoses in a physician’s office, an ambulance or anywhere in the field, including a home; or in a hospital, according to the National Institutes of Health (NIH).

In its "fact sheet," the NIH stated: "Empowering clinicians to make decisions at the ‘point-of-care’ has the potential to significantly impact health care delivery and to address the challenges of health disparities."